AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05669144 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: mitochondria and MSC-derived exosomes
Description: autologous mitochondria and MSC-derived exosomes
Study NCT05042804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Machine learning models predicting postoperative death and acute kidney injury
Description: The machine learning display uses data from the electronic health record to predict the likelihood of postoperative death and postoperative acute kidney injury.
Study NCT05603481 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
Study NCT04722146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Participants will receive nirogacestat.
Study NCT04384835 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample collection (one tube)
Description: Collection of one tube of 7.5 ml blood in addition to a blood sample made in clinical practice
Study NCT04384835 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample collection (five tubes)
Description: Collection of five tubes of 7.5 ml blood in addition to a blood sample made in clinical practice
Study NCT04537832 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT05308498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ESView software with proscan
Description: Each reviewer will review random video and record all lesions/findings with the ESView software with ProScan.
Study NCT05308498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid software with SBI
Description: Each reviewer will review random video and record all lesions/findings with the PillCam Rapid software with SBI.
Study NCT05133869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metacognitive training + direct training
Description: The intervention will consist of a combination of direct training of the impaired cognitive function(s) and metacognitive strategy training for 42 days (6 weeks). Direct training will be done with the computer program Rehacom for 20 minutes, 5 times a week. Metacognitive strategy training will be given on a weekly or biweekly basis (6-10 sessions) by a trained therapist at Adelante.~Rehacom is a brain training program developed to improve a variety of cognitive functions with the use of game-like cognitive training modules. During the intervention the participant should train with Rehacom for approximately 600 minutes in total.~In addition to the direct training, the participant receives six to ten sessions of metacognitive strategy training. During this training they are taught strategies by a therapist to improve their performance on the Rehacom modules and on daily life functioning. Each metacognitive strategy is linked to one of the Rehacom modules.
Study NCT06206135 — intervention group
Intervention type: DRUG
Intervention: the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)
Description: The initial dose of Nephoxil capsules for the subjects participating in this study shall be determined at the investigator's discretion, and subjects shall be classified into either the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) according to the initial dose. It will be conducted with 13 visits over 48 weeks.
Study NCT04676867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalcetrapib
Description: Dalcetrapib 300 mg Film-Coated Tablets
Study NCT04676867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets
Study NCT04495868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacteriostatic Normal Saline
Description: A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study NCT04495868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic Normal Saline
Description: A skin wheal will be made with bacteriostatic normal saline (BNS). BNS contains 0.9% benzyl alcohol and benzyl alcohol is an opium alkaloid that is sometimes added to physiologic normal saline for its bacteriostatic properties. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study NCT04495868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Lidocaine
Description: A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study NCT04521387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
Study NCT04521387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
Study NCT04521387 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: injection therapy
Description: The injection will be carried out with aseptic precautions, under regional anesthesia with 1ml of 1% Lignocaine through one puncture of the skin and frequent changes in the inside needle position.
Study NCT04521387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma injection in the painful area of humeral epicondyle.
Study NCT04521387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Injection
Description: Corticosteroid injection in the painful area of humeral epicondyle.
Study NCT04521387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Injection
Description: Hyaluronic acid injection in the painful area of humeral epicondyle.
Study NCT04495868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Lidocaine
Description: A skin wheal will be made with 1% lidocaine. The skin wheal will be created by injecting the medication intra-dermally with a 26 gauge needle.
Study NCT04521387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Saline injection in the painful area of humeral epicondyle.
Study NCT04836390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions
Description: Peripheral blood (PB) ≤ 450 mL and based on donor weight (minimum 10 ml/kg) will be drawn from the HLA-haploidentical donor at least 16 days before the scheduled day of transplant (Day 0). HaploNK cells will be manufactured from the PB of the donor after co-culture with irradiated feeder cells (IFC) as described in Section 2.4. The recipients will receive three NK cell infusions on Day-1, Day+7 (± 1 day) and Day+42 (up to Day+90) from day of transplant (Day 0).
Study NCT06521073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Patient Information Form (HBF): This form, prepared by scanning the literature, includes the patient\&#39;s age, gender, marital status, education level, profession, social security, place of residence, presence of caregivers in the family, from whom he/she receives care, chronic diseases, the side on which knee prosthesis is applied, knee prosthesis. It is a form consisting of questions about your training status, who you received your training from, and your satisfaction with the training.~Barthel Index (BI): Barthel activities of daily living index is an evaluation scale used to measure an individual\&#39;s performance in daily living activities. The index is used for activities of daily living in 10 domains. The Turkish validity and reliability of the Barthel index, developed by Barthel and Mahoney (1965), was determined by Küçükdeveci et al. (17).
Study NCT05651633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride 5mg/g
Description: 1-2 drops up to six times daily for a maximum of 7 days
Study NCT05931679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Headset
Description: A VR headset will be used for participants in the Interactive VR and 360 degree video groups.
Study NCT05931679 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Theatre-based simulation
Description: Traditional theatre-based simulation sessions require the physical presence of interdisciplinary groups of learners caring for a physical mannequin-based patient, where social distancing is challenging.
Study NCT05217433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive leaf extract
Description: The investigational product is a capsule containing 100mg of the active ingredient oleuropein and will be provided once daily in the form of a 250mg olive leaf extract (i.e. 100mg of oleuropein per day) product for the duration of the intervention period (36 days).
Study NCT05217433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control will be a placebo capsule containing 336 mg of cellulose microcrystalline, matching the investigational product appearance.
Study NCT05951010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Anodal stimulation was delivered by a battery-driven stimulator (Neuroelectrics, Barcellona, Spain) through a pair of saline-soaked surface sponge electrodes (7 x 5 cm2) producing a constant current of 2 mA for 20 min. The anode was placed 2 cm under the inion and the cathode was placed over the right deltoid muscle (CD-tDCS) or the spinal lumbar enlargement (2 cm under T11) as described by Benussi et al. (CS-tDCS). An electroconductive gel was applied to the electrodes to reduce contact impedance and the electrodes were held in place using elastic gauzes.
Study NCT04976166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: More informed and detailed education
Study NCT04976166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Shared decision making
Study NCT04976166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: education as usual
Study NCT05496166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
Description: Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
Study NCT05496166 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
Description: Induction treatment stage: SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles. Patients who are able to receive surgery after assessed by two surgons would receive surgery or radiotherapy randomly. Adjuvant/ maintenance treatment stage: SHR-1316，20mg/kg, iv, q3w,up to 1 year
Study NCT06326164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kinesio-taping.
Description: A therapeutic tape that's applied strategically to the body to provide support, reduce pain, swelling and improve performance. Kinesio taping will be applied on both lower limbs. Taping will be applied for 4 days, 24 hours a day, on the lower limbs, and it will be removed for only one day per week.
Study NCT06326164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A designed physiotherapy program.
Description: The designed physiotherapy program included passive stretching, weight bearing, muscle strengthening, functional exercises, neurodevelopmental treatment, splinting, balance training, and gait training. The treatment protocol will be repeated each session per weeks for twelve weeks.
Study NCT05495009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care+virtual reality glasses
Description: At the beginning of the active and transitional phases of labor, videos were watched with virtual reality glasses.
Study NCT04790825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth scaling and root planing (FMSRP)
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
Study NCT04790825 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth scaling and root planing (FMSRP)
Description: Subgingival instrumentation with ultrasonic devices and curettes of all periodontal pockets completed within 48 hours
Study NCT05875194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation (tDCS)
Description: 2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
Study NCT05875194 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active transcranial direct current stimulation (tDCS)
Description: 2mA, over the left dlPFC (10-20 position F3), duration 15 minutes
Study NCT05520489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic stimulation
Description: Participants received 15 sessions (15 daily session - Monday to Friday) of active rTMS over the 'hotspot M1 area of the unaffected hemisphere leading to a response in the contralateral thenar muscle using Visor2-navigation system and MagstimRapid -magnetic stimulator. . Hot spot localization was performed by stimulation with 50%:n intensity and found the maximum response area, where the coil was placed using the navigator cursor. The motor threshold was found using Maximum-Likelihood Strategy -algorithm of MTAT system.~Low frequency rTMS was applied at 80-90% resting motor threshold (rMT) intensity, 1 Hz, 600+600 pulses, inbetween 10 minutes break. Intensity was increased after each 2-3 treatment to keep motor threshold 90%.
Study NCT05520489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot Assisted Therapy
Description: This was delivered using the Diego and Pablo (Tyromotion GmBH) robotic gym system. Participants receive robot-assisted training for up to 60 min per day, four days per week for 3 weeks, in addition to usual care. Robotic devices enable 3D interactive exercising, using weight reducing system in Diego and fine motor training in Pablo. Exercises can be one- or two-handed and/or symmetrical. Patient performs 150-400 repetitions in one therapy session. Estimated time is 2-3 minutes per one exercise section. Standard minimum program includes 4 games: swimming, shooting, ship and apple orchard. The therapist instructs the patient and assure the position of trunk and shoulder girdle.
Study NCT05520489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced upper limb therapy programme
Description: Exercises were performed by using different objects for task orientated movements. The therapist provided assistance as needed and encouraged participants to complete the tasks. Training was divided to 3 sessions for fine motor training and complex training and 1 session for shoulder girdle and complex training per week for 3 weeks, in addition to usual care. Each session lasts 1 hour and estimated time is 2-5 min to each exercise section.
Study NCT05840627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice
Description: Daily consumption of 200 mL of fruit juice at lunch for 14 consecutive days, provided by the research team.
Study NCT04651699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation
Description: The Starstim tDCS® stimulator will be used by an experienced physical therapist to transfer direct current by a saline-soak pair of surface sponge electrodes (35cm2). The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1 (32). Regarding the stimulated hemisphere, contralateral M1 will be stimulated in patients with asymmetric pain and the dominant (contrary to the dominant hand determined by the Edinburgh Handedness Inventory) in patients with symmetric pain, due to the widespread changes induced by tDCS in other cortical areas, including contralateral M1. A constant current of 2 milli amps intensity (subthreshold intensity) will be applied for 20 min, with 30 seconds of ramp-up and 30 seconds of ramp-down.
Study NCT04651699 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The electrodes will be placed in the same positions as for M1 stimulation, but only applying ramping active current for 30 seconds in the beginning and at the end of the procedure for a reliable blinding.
Study NCT05763836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 Mg in 8 mL INTRAVENOUS INJECTION [Caldolor]
Description: Intravenous ibuprofen infusion
Study NCT05763836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalp nerve block
Description: Scalp nerves blocked by using local anesthetics
Study NCT05763836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp nerve block
Description: Scalp nerves blocked by using local anesthetics
Study NCT05027932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IN Placebo
Description: The placebo will be normal saline in two syringes administered IN.
Study NCT05458674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: taken orally
Study NCT05458674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: taknen intravenously
Study NCT05027932 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IN Placebo
Description: The placebo will be normal saline in two syringes administered IN.
Study NCT05027932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IM Placebo
Description: The placebo will be normal saline in a syringe administered IM.
Study NCT05027932 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: IM Placebo
Description: The placebo will be normal saline in a syringe administered IM.
Study NCT05027932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPL-1357
Description: BPL-1357 contains 4 whole inactivated avian influenza viruses: A /Environment /Maryland/261/2006 H7N3, A/Mallard /Maryland/802/2007 H5N1, A/Pintail/Ohio /339/1987 H3N8, and A/Mallard/Ohio /265/1987 H1N9. It will be administered either IM or IN depending on the assigned treatment group.
Study NCT05458674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: taken intravenously
Study NCT05275140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Combat sports and exercise
Study NCT05275140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Combat sports and exercise
Study NCT04399993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Protocol in Diaphragm
Description: The protocol consists of three techniques. The two first techniques will be applied for 10 respiratory cycles.~Muscle Stretching Technique:~the researcher will perform a cephalic traction on the inferior costal border with the ulnar border during the inspiratory phase.~Phrenic-center inhibition technique:~the researcher, with a hand on the sternum to caudal and other hand on the umbilical region to cranial, will approach his hands on the horizontal plane, when the volunteer exales.~Functional diaphragm technique:~the researcher will perform a vertical pressure on the diaphragm for 5 minutes and will search for the facilitated parameters and maintain them until the release of all the periarticular elements.
Study NCT04399993 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham technique
Description: In the sham group a manual contact without any therapeutic intention will be performed, in a distant region of the diaphragm (for example on the trapezius muscle). This contact will be maintained during the same amount of time as for the treatment group.
Study NCT06138405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate intervention Group
Description: The immediate intervention group will be video recorded in office and participate in the training workshop and assessment methods two months after.
Study NCT06138405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention (control) Group
Description: The delayed training group will also be video recorded in office but will wait an additional two months and then participate in the training and assessment methods as with the original training group.
Study NCT05418153 — intervention group
Intervention type: DEVICE
Intervention: Tecnis Synergy IOL
Description: Intraocular lens replaces the natural lens removed during cataract surgery in both eyes.
Study NCT05411861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic Non Narcotic
Description: Injection of protocol-specified volume of local analgesic
Study NCT05411861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesic Non Narcotic
Description: Injection of protocol-specified volume of local analgesic
Study NCT05411861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic Non Narcotic
Description: Injection of protocol-specified volume of local analgesic
Study NCT05835544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: HIIT Control
Description: Complete 3 sets of five repetitions of 30 seconds cycling at 100% of maximal aerobic power with 30 seconds of active unloaded recovery between repetitions; 3 minutes of passive rest between sets.